Summary
Cardiac Care Support covers the services that help people with established or high-risk heart disease after diagnosis or an acute event, including cardiac rehabilitation, monitoring, education and supporting diagnostics. The disease burden is large. The World Health Organization estimates 19.8 million cardiovascular deaths, about 32% of all deaths 2, and projects mortality to rise with ageing 1. Access is uneven. Cardiac rehabilitation is offered in 68.0% of high-income countries but 23% of low- and middle-income countries 5, and fewer than half of eligible patients are referred 5. In the United States, projections show cardiologist demand growing faster than supply 8. The pack contains no verified market size, spending, provider cost or staffing data for this service line. Principal risks are workforce shortage, referral gaps and limited outcome evidence for digital delivery. The outlook favours providers and health systems that build reliable referral pathways and task-sharing models.
Key findings
-
1
The disease burden is large and concentrated in lower-income countries
The WHO estimates 19.8 million CVD deaths, about 32% of all global deaths, and reports that over three quarters of CVD deaths occur in low- and middle-income countries.
Confidence: High -
2
Referral is the main gap in the care pathway
Fewer than half of eligible patients worldwide are referred to cardiac rehabilitation, and only 34.4% of surveyed patients in fourteen countries reported being advised to join a program.
Confidence: Medium -
3
Program availability differs sharply by income level
Cardiac rehabilitation is offered in 68.0% of high-income countries compared with 23% of low- and middle-income countries. Survey periods are not stated on the page.
Confidence: Medium -
4
US cardiologist demand is projected to outpace supply
Demand is projected to rise 15.7% while supply rises 2.0%, and workforce adequacy is projected to fall from 92.2% to 81.4%, with nonmetropolitan areas lower. These are model projections.
Confidence: Medium -
5
Task-sharing offers a practical route to diagnostic capacity
Kenya has about 40 cardiologists alongside 350 internal medicine physicians and 25,000 clinical officers, and a 16-week transthoracic echocardiography training program was launched to address the diagnostic gap.
Confidence: Qualitative
11. Industry definition and scope
This report treats Cardiac Care Support as a service line rather than a single product market. In this report it covers services for people with established or high-risk heart disease after diagnosis or an acute event, including cardiac rehabilitation, risk-factor support, monitoring, patient education and supporting diagnostics such as echocardiography. The source pack does not define the industry, so these boundaries are the writer's working definition.
Cardiovascular disease (CVD) is the disease family used across the sources. Ischaemic heart disease is projected to remain the leading cause of cardiovascular deaths 1. Sources use different measures: the WHO reports CVD deaths 2, the Institute for Health Metrics and Evaluation reports deaths and people affected 3, and the British Heart Foundation reports prevalence and incidence estimates 4. These measures are not directly interchangeable.
The geographic scope is global. The pack includes national examples from the United States, Hungary and Kenya, and a fourteen-country survey across six WHO regions 6. Japan appears in the scope label, but the pack contains no Japan-specific evidence. Reporting uses the latest available data. Several sources do not state their survey or registry periods, so time comparisons are approximate.
This analysis describes system-level patterns. It is not individual medical advice and does not assess the care of any specific patient.
Boundaries were set by the writer. No external definition was taken from the pack.
Assumptions behind these figures
- Cardiac Care Support is defined by the writer as post-diagnosis and secondary-prevention support services, since the pack provides no industry definition.
22. Market size, structure and value chain
The pack contains no verified global market size, revenue or spending figure for cardiac care services, devices or digital cardiac rehabilitation. Market size and growth therefore cannot be stated. The disease burden is the only quantified demand base available.
The British Heart Foundation estimates that around 650 million people live with cardiovascular disease worldwide and that around 53 million people develop it each year 4. These are estimates. The Institute for Health Metrics and Evaluation reports that ischaemic heart disease affected an estimated 240 million people in its latest period 3. The gap between these figures reflects differences in definitions and methods.
Mortality is the clearest measure of scale. The WHO estimates 19.8 million CVD deaths 2. The IHME reports a rise from 13.1 million to 19.2 million CVD deaths over its study period 3. A peer-reviewed projection estimates global cardiovascular mortality could rise to 35.6 million deaths per year, driven by ageing populations 1. This is a forecast, not an observed figure.
The value chain is not quantified in the pack. In this writer's interpretation, it runs from detection in primary care and hospital diagnosis, through referral to rehabilitation or follow-up services, to community support and monitoring. Stakeholders include health systems, cardiology and rehabilitation teams, nursing and allied staff, equipment and digital suppliers, and payers. Revenue models and payment rates for these services are not in the pack and are not compared here.
- Cardiovascular deaths per year 19.8million deaths Observed Global, Latest available data [2]
- Share of all global deaths from CVD 32percent Observed Global, Latest available data [2]
- People living with cardiovascular disease 650million people (estimate) Estimate Global, Latest available data [4]
Disease burden figures are drawn from different organizations with different definitions and should not be summed.
Assumptions behind these figures
- Market value is treated as unavailable; the KPIs describe disease burden only.
33. Customers, demand and adoption
The end users are patients after heart attacks, stents, bypass surgery or diagnosis of chronic heart disease, along with their families. Demand is shaped by the number of patients eligible for support and by whether clinicians refer them. Ageing is the main demand driver in the forecasts 1.
Referral is the weakest link in the pathway. Fewer than half of eligible patients worldwide are referred to cardiac rehabilitation 5. In a fourteen-country survey, only 34.4% of patients reported being advised to join a program 6. Referral reports ranged from 4.0% in Kenya to 69.6% in Poland 6. Among all recruited patients, only 19.6% attended at least half of their sessions 6, which shows that referral alone does not guarantee use.
National data from Hungary show that participation in comprehensive cardiac rehabilitation among early acute coronary syndrome survivors was 17.4% 7. The same registry analysis reports a 34% reduction in long-term all-cause mortality associated with rehabilitation 7. This is an association from registry data, not proof of cause. Purchasing criteria used by patients, payers or employers are not covered in the pack.
Barriers include the absence of primary care programs for early detection and treatment of risk in many lower-income countries 2. Expectations about digital support are rising in the writer's view, but the pack gives no adoption data for digital services.
- Patients advised to join cardiac rehabilitation 34.4percent of surveyed patients Observed Fourteen countries across six WHO regions, Survey period not stated [6]
The Hungary association and the referral survey come from different designs and should not be combined into one estimate.
Assumptions behind these figures
- Income group comparisons use the same source and definitions, so they are internally consistent.
44. Competitive landscape and key players
The pack does not identify commercial companies, market shares or concentration measures for Cardiac Care Support. The organizations it names are mainly data publishers, including the WHO, the IHME, the British Heart Foundation and Medscape. These are not competitors in the service market, so they are not compared as providers.
Provider types can be described in general terms: public hospitals and health systems, private hospitals and clinics, and community or program-based services. The pack contains no utilization, waiting-time or cost-per-episode data that would allow a fair comparison of public, private and community providers for cardiac rehabilitation or support. This is a major gap.
Program-level examples are available. In Kenya, a Kenya Cardiac Society and American College of Cardiology program launched a 16-week transthoracic echocardiography training course to address a diagnostic gap 10. The Hungarian nationwide registry analysis provides a system-level view of rehabilitation participation 7. A registered digital cardiac rehabilitation trial is listed in the pack (ClinicalTrials.gov NCT06813482), but it has no verified outcome results.
Business models, differentiation and competitive pressures cannot be compared on evidence in the pack. The writer's interpretation is that competition in this service line is mainly for referral volume, qualified staff and reimbursed program slots, rather than for product share. This interpretation is not supported by a quantified source.
Examples were limited to programs and national registries because the pack contains no comparable company data.
Assumptions behind these figures
- Provider types are described for orientation only and are not ranked.
55. Technology, operations and workforce
Established practice includes center-based cardiac rehabilitation, which is available in 68.0% of high-income countries 5. Diagnostic echocardiography is an established tool, and the Kenyan program shows how training can extend diagnostic capacity beyond cardiologists 10. The pack does not give evidence on productivity gains from these practices.
Emerging approaches include digital cardiac rehabilitation. The pack identifies a registered trial but contains no verified outcome results, so the evidence for digital delivery is currently weak in this source set. The writer's view is that digital tools may help reach patients where specialists are scarce, but this needs outcome data before it can be assessed.
Workforce pressure is documented for the United States. A peer-reviewed projection estimates cardiologist supply will rise 2.0%, from 37,000 to 37,730 full-time equivalents, while demand rises 15.7%, from 40,110 to 46,390 8. Workforce adequacy is projected to fall from 92.2% to 81.4%, with nonmetropolitan areas lower 8. Interventional cardiology filled 236 of 307 available positions, or 76.9% 9. This figure comes from a news report and reflects a specific year.
No comparable data on nurses, allied health professionals or cardiac technologists was found in the pack. Staffing for cardiac care support therefore cannot be assessed on a global basis.
| Indicator | Starting point | Later projection | Projected change | Value type |
|---|---|---|---|---|
| Cardiologist supply (FTE) | 37,000 | 37,730 | +2.0% | Forecast |
| Cardiologist demand (FTE) | 40,110 | 46,390 | +15.7% | Forecast |
| Workforce adequacy (percent) | 92.2% | 81.4% | Decline of 10.8 points | Forecast |
Projections are model outputs and depend on their assumptions. The adequacy figures are not checked against primary federal publications.
Assumptions behind these figures
- The projection uses the Health Workforce Simulation Model as reported in S8.
- The point difference in adequacy is calculated from the two reported percentages.
66. Regulation, standards, risk and sustainability
The pack contains no binding laws, regulator rules, clinical standards or proposed regulations for cardiac care support in the United States, Hungary, Japan or Kenya. The report therefore cannot distinguish binding requirements from proposals or voluntary guidance. Anyone relying on this analysis for regulatory decisions should check the rules in the relevant jurisdiction.
Evidence quality varies. The sources include a registry analysis 7, a cross-sectional survey 6, a peer-reviewed scoping review referenced in the gaps and projection models 18. None of them is a randomised comparison of cardiac care support models in the pack. Outcome claims should be read as associations unless the source states otherwise.
Privacy is relevant because registry and survey data describe identifiable patient groups. This report uses only aggregate figures. Digital monitoring would add data-protection duties, but the pack does not describe the rules that apply, so the writer does not assess them.
Operational risk is concentrated in workforce and geography. Medscape reports that about 86% of rural US counties had no cardiologists in a recent year 9. This is secondary reporting, and the pack does not confirm the underlying primary data. Environmental and sustainability factors for cardiac care support are not covered in the pack.
- Rural US counties with no cardiologists 86percent of rural counties Observed United States, Recent year (secondary reporting) [9]
Regulatory content is left out because no verified regulatory source is in the pack.
77. Challenges, opportunities and case examples
The main constraints are referral gaps, low session attendance, limited program availability in lower-income countries and a projected shortfall of cardiologists in the United States. Patients in lower-income countries often lack primary care programs for early detection and treatment of risk 2. These constraints affect both access and outcomes.
The opportunities are practical. Referral rates show wide variation between countries, from 4.0% in Kenya to 69.6% in Poland 6. The causes of that variation are not explained in the pack, but it suggests that referral practice can change. Task-sharing in diagnosis, as in the Kenyan echocardiography program 10, offers a way to add capacity where cardiologists are few.
Case example 1: Kenya. The country has about 40 cardiologists, 350 internal medicine physicians and 25,000 clinical officers 10. A 16-week echocardiography program was launched to address the diagnostic gap 10. The pack does not report outcomes from this program.
Case example 2: Hungary. A nationwide registry shows 17.4% participation in comprehensive cardiac rehabilitation among early acute coronary syndrome survivors and an association with a 34% reduction in long-term all-cause mortality 7. Registry data show associations and cannot establish how much of the reduction is caused by rehabilitation.
Case example 3: Poland. Referral reports reached 69.6% in a fourteen-country survey 6. Because this is survey-reported referral, it is not a verified national program figure.
Three country-level examples are used because the pack contains no company case studies with verified outcomes.
Assumptions behind these figures
- The case examples are illustrative of system patterns in the sources, not endorsements of any provider.
88. Outlook and strategic implications
In the near to medium term, demand is likely to rise with ageing populations 1. The projected 30.5% fall in age-standardized cardiovascular mortality is a forecast that depends on improved post-diagnosis care 1. Realising that gain would require higher referral and attendance rates than the survey evidence currently shows 56.
The United States workforce gap is projected to widen, with adequacy falling to 81.4% and nonmetropolitan areas lower 8. Scenario analysis is not available in the pack, so the writer's interpretation is that delay in workforce planning would widen this gap, but this cannot be quantified from the sources.
Practical implications differ by stakeholder. Health systems and referral networks should measure referral and attendance, since these are the clearest access gaps. Workforce planners should evaluate task-sharing models, as the Kenyan training shows 10. Digital providers should publish outcome results before claiming clinical benefit, because the pack contains no verified outcomes. Payers and funders need cost and utilization data, which are missing from the pack. Researchers should close the data gaps listed in the methodology callout.
Scenarios are qualitative because the pack lacks cost, spending and utilization data.
Assumptions behind these figures
- Outlook statements are the writer's interpretation of the forecasts and survey evidence, not predictions.
99. Conclusion
Cardiac Care Support addresses a large and growing disease burden. The most defensible takeaways are that referral is the weakest link in the pathway, that access differs sharply by income level, and that US cardiologist demand is projected to outpace supply. Market size and provider comparisons remain unverified.
How this was built
This report uses only the verified source pack. Figures are labelled by value type (observed, estimated or forecast) and cited to sources. Interpretations are labelled as the writer's view. Scope is global, with national examples from the United States, Hungary and Kenya. The latest available data are used, but several sources do not state their survey periods.
Limits to keep in mind
- No verified market size, revenue, spending or growth figures were found for cardiac care services, devices or digital cardiac rehabilitation.
- No comparable data on cardiac care support staffing (nurses, allied health, cardiac technologists) was found.
- Public, private and community provider comparisons (utilization, waiting times, cost per episode) were not found.
- Waiting-time and outcome indicators by provider type were not retrieved.
- Digital cardiac rehabilitation evidence is limited to a registered trial listing with no verified outcome results.
- The survey periods for the cardiac rehabilitation survey and the fourteen-country survey are not stated on the pages, so timing is approximate. The Nature Reviews Cardiology article is an older publication, so its availability figures are indicative only.
Sources
-
1
Global burden of cardiovascular diseases: projections for the coming decades
academic.oup.com -
2
Cardiovascular diseases (CVDs) fact sheet
who.int -
3
Report: cardiovascular diseases caused 1 in 3 global deaths in the latest period
healthdata.org -
4
BHF Global Cardiovascular Disease Factsheet (January edition)
bhf.org.uk -
5
Global availability of cardiac rehabilitation
nature.com -
6
INTERASPIRE: Cardiac Rehabilitation in Patients with Coronary Heart Disease, fourteen countries across six WHO regions
globalheartjournal.com -
7
Comprehensive cardiac rehabilitation program enhances outcomes among early survivors of acute coronary syndrome: nationwide registry analysis
pmc.ncbi.nlm.nih.gov -
8
Assessing Supply, Demand, and Adequacy of Cardiologists in the United States: Projecting a National Shortage
pubmed.ncbi.nlm.nih.gov -
9
Cardiology Crunch: An Aging Nation, More Patients, Fewer Clinicians
medscape.com -
10
Kenya cardiovascular disease care beyond the cardiologist: transthoracic echocardiography training
ncbi.nlm.nih.gov